Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-465.32	-298.41	-214.53	-163.92	-107.64
Depreciation & Amortization	3.89	2.79	1.1	0.98	0.92
Loss (Gain) From Sale of Assets	0.05	0.05	0.01	-	-
Loss (Gain) From Sale of Investments	-15.43	-14.93	-6.27	0.03	0.42
Loss (Gain) on Equity Investments	-	0.47	5.2	1.01	-
Stock-Based Compensation	91.02	69.39	40.94	28.27	17.35
Other Operating Activities	3.01	3.04	-0.79	-0.19	-0.74
Change in Accounts Receivable	-0.59	-	-	-	-
Change in Inventory	-2.02	-	-	-	-
Change in Accounts Payable	28.98	17.54	14.65	10.99	6.29
Change in Unearned Revenue	-1.84	0.07	-1.54	8.34	-
Change in Other Net Operating Assets	-19.69	-5.98	-5.07	-0.72	-5.2
Operating Cash Flow	-377.92	-225.97	-166.31	-115.21	-88.59
Capital Expenditures	-5.76	-3.84	-4.69	-1.66	-0.44
Investment in Securities	179.67	-570.97	-195.73	-172.32	-56.05
Investing Cash Flow	173.91	-574.82	-200.41	-173.98	-56.48
Issuance of Common Stock	40.61	1,060	411.68	129.72	265.64
Other Financing Activities	-	-49.44	-22.74	-7.76	-12.96
Financing Cash Flow	40.61	1,010	388.94	121.96	252.68
Foreign Exchange Rate Adjustments	-0.11	-	-	-	-
Net Cash Flow	-163.51	209.65	22.22	-167.22	107.61
Free Cash Flow	-383.68	-229.81	-171	-116.86	-89.02
Free Cash Flow Margin	-4985.50%	-22118.77%	-4261.03%	-2466.98%	-8258.26%
Free Cash Flow Per Share	-4.08	-2.85	-2.94	-2.25	-2.32
Levered Free Cash Flow	-297.94	-136.41	-93.53	-62.51	-48.47
Unlevered Free Cash Flow	-297.94	-136.41	-93.53	-62.51	-48.47
Change in Working Capital	4.84	11.64	8.04	18.61	1.1

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q